More tools

Corvus Pharmaceuticals, Inc.

CRVS

Corvus Pharmaceuticals, Inc.

3.21

0.04

(1.26%)

Today

As of 4:00 PM Eastern

After Hours:

3.21

0.00

Options AI - All Directions

Apr 17 Expected Move

See where the options market thinks CRVS will move from here.

2025-03-03 09:30:002025-03-13 13:00:002025-03-25 16:30:002025-04-07 12:00:002025-04-17 15:30:00$3.70$2.72

Corvus Pharmaceuticals, Inc.

Market Cap: 218.72 million

PE Ratio: -3.15

Volume: 884.89 thousand

Sector: Healthcare

Industry: Biotechnology

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.